----0 - getGroupsByUser
Array ( [0] => stdClass Object ( [title] => Public ) )
----0 - getAuthorisedViewLevels
Array ( [0] => 1 [1] => 1 )
----0 - groups
Array ( [0] => 1 )

Translate page

Presentations from the 23rd Congress of EHA 

We are pleased to make available a couple of presentations on various aspects of CML management that were first presented at the 23rd Congress of the European Hematology Association in Stockholm. Presentations include; treatment options in resistant CML patients, Does IFN-α improve outcome of CML in the TKI era? and TFR - a new goal for CP-CML patients?

 
EHA 2018 Apperley


Treatment options in resistant CML patients
Professor Jane Apperley, Imperial College London, UK 

  • Patient case history 2013 - 2017
  • ELN and NCCN definitions of response and failure
  • Outcome of 'real-life' 1st line imatinib by Sokol
  • Importance of ACA
  • ABL KD mutation sensitivity
  • CCyR rates for sequential use of NIL and DAS after IM failure
  • 3rd line therapy with Bosutinib
  • Relationship of line of therapy to efficacy for PON in 3rd-line vs. 4th line CML
  • SCT for CML: the EBMT score

We are very grateful for the support of Brandcast media to produce these webstreams.